Volume | 418,093 |
|
|||||
News | (4) | ||||||
Day High | 280.00 | Low High |
|||||
Day Low | 268.07 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
275.00 | 268.07 | 280.00 | 277.59 | 277.02 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
13,419 | 418,093 | $ 275.92 | $ 115,362,073 | - | 119.7604 - 298.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:45:18 | 10 | $ 277.59 | USD |
Madrigal Pharmaceuticals (MDGL) Options Flow Summary
Madrigal Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.52B | 19.90M | - | 0 | -373.63M | -18.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Madrigal Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 236.75 | 295.50 | 227.78 | 278.36 | 749,763 | 40.84 | 17.25% |
1 Month | 217.53 | 295.50 | 208.60 | 248.64 | 626,644 | 60.06 | 27.61% |
3 Months | 258.49 | 295.50 | 189.00 | 235.35 | 480,527 | 19.10 | 7.39% |
6 Months | 231.04 | 298.00 | 168.2462 | 234.19 | 510,884 | 46.55 | 20.15% |
1 Year | 268.00 | 298.00 | 119.7604 | 209.64 | 458,085 | 9.59 | 3.58% |
3 Years | 108.86 | 322.67 | 52.33 | 183.69 | 334,468 | 168.73 | 155.00% |
5 Years | 103.23 | 322.67 | 52.33 | 163.21 | 266,544 | 174.36 | 168.90% |
Madrigal Pharmaceuticals Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |